دورية أكاديمية
أعرض في EDS

Opportunities on the horizon for the management of early colon cancer.

التفاصيل البيبلوغرافية
العنوان: Opportunities on the horizon for the management of early colon cancer.
المؤلفون: Knapen DG; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands., de Haan JJ; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands., Fehrmann RSN; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands., de Vries EGE; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands., de Groot DJA; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: d.j.a.de.groot@umcg.nl.
المصدر: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2023 Mar; Vol. 183, pp. 103918. Date of Electronic Publication: 2023 Jan 23.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005->: Amsterdam : Elsevier Scientific Publishers
Original Publication: Boca Raton, Fla. : CRC Press, 1983-
مواضيع طبية MeSH: Colonic Neoplasms*/genetics , Rectal Neoplasms*, Humans ; Chemotherapy, Adjuvant ; Microsatellite Instability
مستخلص: There is a clear unmet need to improve early colon cancer management. This review encompasses the current systemic treatment landscape and summarises novel and pivotal trials. The Immunoscore and circulating tumour DNA (ctDNA) are studied to evaluate which patients should receive no, 3, or 6 months of adjuvant treatment. Several trials also test escalating treatment strategies for non-cleared ctDNA following standard adjuvant chemotherapy. Advances made in treating patients with metastatic colon cancer are now being translated to the early colon cancer setting. Two ongoing RCTs study immune checkpoint inhibitors (ICI) in patients with microsatellite instable high (MSI-H) early colon cancer as adjuvant treatment. Neo-adjuvant treatment is being studied in several ongoing RCTs as well. The complete response rate in patients with MSI-H tumours following ICI in neoadjuvant trials has potential organ-sparing implications.
Competing Interests: Conflict of Interest Statement De Vries reports Institutional financial support for her advisory role from Daiichi Sankyo, Merck, NSABP, Pfizer, Sanofi, Synthon, and institutional financial support for clinical trials or research from Amgen, AstraZeneca, Bayer, Chugai Pharma, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Synthon, all outside the submitted work. De Groot reports institutional financial support for clinical trials or contracted research from Roche/Genentech, BMS, and Ipsen. The other authors do not report any conflict of interest.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: (Neo)adjuvant; CtDNA; Early colon cancer; Immunoscore; Immunotherapy
تواريخ الأحداث: Date Created: 20230126 Date Completed: 20230227 Latest Revision: 20230227
رمز التحديث: 20230227
DOI: 10.1016/j.critrevonc.2023.103918
PMID: 36702421
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-0461
DOI:10.1016/j.critrevonc.2023.103918